Business
CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date
More than 100,000 CytoSorb treatments delivered, tens of thousands of patients treated, and many lives saved MONMOUTH JUNCTION, N.J., Aug. 3, 2020
About this update from Cytosorbents Corporation
[{"type":"text","content":"More than 100,000 CytoSorb treatments delivered, tens of thousands of patients treated, and many lives saved\n\n\nMONMOUTH JUNCTION, N.J., Aug. 3, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces that it has reached a major milestone in the history of the company with the cumulative delivery of more than 100,000 CytoSorb cartridges to date to hospitals around the world, including those here in the United States. CytoSorb is distributed in a total of 65 countries globally.\n\n \n \n \n \n \n \n\n \nThe CytoSorbents management team, including CEO Dr. Phillip Chan, President and COO Vincent Capponi, CFO Kathleen Bloch, CMO Dr. Efthymios Deliargyris, Senior Vice President of Sales and Marketing and Managing Director of CytoSorbents Europe GmbH Dr. Christian Steiner, and Vice President of Business Development Christopher Cramer, commented in a joint statement:\nCytoSorb is Changing Medicine\n\"Changing the practice of medicine is neither quick nor easy, particularly when patients' lives are at stake. But we are doing this with our CytoSorb® blood purification therapy, now with more than 100,000 treatments delivered cumulatively to date, with tens of thousands of patients treated, and many lives saved.\"\nOne CytoSorb, Many Life-saving Applications\n\"The journey began with the vision that CytoSorb blood purification could calm the \"cytokine storm\" and deadly inflammation that often leads to organ dysfunction and failure, and in many cases death, in patients with sepsis. Sepsis and septic shock are the result of an overzealous immune response to a severe infection that is responsible for 1 in 5 deaths worldwide. But through collaboration with the medical and scientific research community, particularly those who ventured 'outside the box' for treatment alternatives to major unmet medical needs, the uses of CytoSorb have continued to flourish. These applications now encompass the treatment of a wide range of life-threatening conditions such as trauma, refractory shock, acute respiratory distress syndrome (ARDS), complications of SARS-CoV-2 (COVID-19) infection, influenza, burn injury, acute liver failure, cytokine release syndrome in ...